Why the FDA should not approve an ineffective multicancer screening test

An FDA advisory committee recommends approving Grail’s multi-cancer screening test. A cancer screening researcher disagrees.

Grail的多癌種血液篩查試驗未能在替代終點上顯示獲益，FDA顧問委員會卻建議批准，作者認為缺乏降低癌症死亡率的證據。文章還指出，新法案將使聯邦醫保快速覆蓋該檢測，可能帶來每年數百億美元的支出。